Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01692353
Other study ID # RJRT-CSD0806
Secondary ID
Status Completed
Phase N/A
First received August 13, 2012
Last updated February 15, 2016
Start date September 2008
Est. completion date April 2009

Study information

Verified date February 2016
Source R.J. Reynolds Tobacco Company
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This cross-sectional study was primarily a cardiovascular disease (CVD) study designed a) to compare selected CVD biomarker data between subjects who were long-term consumers of cigarettes or moist snuff and non-consumers of tobacco and b) to identify principal endpoints related to CVD risk that differed among the three tobacco-use cohorts. The following assessments provided the primary study endpoints for comparative analyses between the cohorts:

1. CVD-related physiological assessments: Flow-mediated dilation (FMD), carotid intima-media thickness (CIMT), ankle-brachial index (ABI), spirometry and expired carbon monoxide (ECO).

2. CVD-related biomarker assessments in blood and urine (biomarkers of tobacco effect).

3. Biomarkers of tobacco exposure in urine and blood.


Description:

This single site, observational study will provide an increased understanding of how consumption of different tobacco products (i.e., cigarettes and moist snuff compared to no tobacco use) affects 1) CVD-related physiological assessments and 2) CVD-related biomarkers of tobacco effect (i.e., proteins, lipids, and cellular components). A recent policy statement from the American Heart Association provides a review and analysis of the impact of smokeless (ST) use on cardiovascular disease (CVD) (Piano et al. 2010). The authors acknowledge that the evidence is consistent with the suggestion that the cardiovascular risks from ST products are markedly lower than those from cigarette smoking. Despite the potential risk reduction in transitioning from cigarettes to ST consumption, few studies have directly compared biomarkers of tobacco effect (BioEff) among smokers, moist snuff consumers (MSC) and non-tobacco consumers (NTC).

Furthermore, this study will measure biomarkers of tobacco exposure to assess their ability to differentiate the three tobacco consumer groups (smokers, moist snuff consumers, non-tobacco consumers) based on product use. Estimating exposures to combustion-related compounds found in tobacco smoke is best accomplished using biomarkers. A key advantage of human exposure biomarkers is that they are considered reliable metrics of the levels of exposure that consumers actually experience when using tobacco products (Hecht et al., 2010). Because combustion does not occur during ST use, ST products lack most of the combustion-related compounds found in tobacco smoke. Biomarker differences found between different tobacco use groups to harmful or potentially harmful constituents may indicate differences in subsequent health risks (Rodu and Godshall, 2006; Hatsukami et al., 2006).

Epidemiological data demonstrate that the health risks associated with cigarettes are significantly greater than those associated with the use of non-combustible tobacco and nicotine products (Surgeon General, 2010). On a relative risk continuum, cigarette smoking presents a significantly greater risk to tobacco users than use of non-combustible smokeless products. ST products, which are consumed orally, do no generate chemicals associated with the burning of tobacco, and thus, present a reduced toxicant profile compared to smoking.

To address the purpose and objectives of this study, the study was conducted as follows:

- Subjects were consented for the study prior to any procedures being performed and screened on study-specific inclusion/exclusion criteria to determine subject eligibility (within 28 days of study check-in).

- Eligible subjects were admitted to the clinical research unit between 12:00 noon and 5:00 p.m. on Day 1 and confined for one overnight stay (approximately 18-23 hours).

- After all study procedures were completed on Day 1 and Day 2, appropriate basic safety assessments were made and subjects were discharged approximately at 12:00 noon on Day 2.

A brief description of the study procedures performed is listed below.

- After check-in on Day 1, eligible subjects observed a 45-minute tobacco abstention period, followed by use of a single unit of their usual brand (UB) tobacco product, referred to as a "Challenge." For smokers, the "challenge" was smoking one UB cigarette in their usual manner; for moist snuff consumers, a 30-minute use of one typical pinch of their UB moist snuff.

- Fifteen minutes after the end of UB use, the following procedures were performed sequentially: ECO; blood samples for biomarkers of exposure (serum nicotine and cotinine, percent carboxyhemoglobin in whole blood); and ABI.

- At 30 minutes post-UB use, FMD was measured followed by administration of health-related questionnaires. The non-tobacco consumers had no product "Challenge". The completion of study questionnaires served as the reference point for collection of ECO, ABI and FMD.

- Blood biomarkers of tobacco exposure were collected on Day 1 following product "Challenge" and on Day 2 following an overnight tobacco abstention and fast.

- Urine biomarkers of tobacco exposure and effect were collected on both Day 1 post-"Challenge" and on Day 2 fasting.

- Blood biomarkers of tobacco effect were only collected on Day 2 fasting, followed by the re-assessment of the physiological measures (ECO, ABI, FMD) and assessment of CIMT.


Recruitment information / eligibility

Status Completed
Enrollment 168
Est. completion date April 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 26 Years to 49 Years
Eligibility Inclusion Criteria:

- Smokers: exclusive FF (full flavor; > 13.0 mg FTC "tar" ) or FFLT (full flavor, low "tar" [6.0 to 13.0 mg FTC "tar"]) smokers who reported smoking at least 15 cigarettes daily for at least three years prior to Day 1 and whose ECO was 10 to 100 ppm (ranges of 2 to 9 ppm and 101 to 125 ppm were allowed upon joint review by the Sponsor and Investigator).

- Moist Snuff Consumers: exclusive oral smokeless tobacco users of any brand (Copenhagen, Skoal, Grizzly, Kodiak, Timber Wolf, Longhorn, Red Man, Levi Garrett, Beech-Nut, Chattanooga Chew, Kayak, etc.), any style (snuff cut, long cut, fine cut, pouch, loose, or plug) and any flavor (natural, straight, mint, wintergreen, etc.) who reported using at least two cans or packages per week for at least three years prior to Day 1 and whose ECO was 0 to 5 ppm (a range of 6 to 10 ppm was allowed upon joint review by the Sponsor and Investigator).

- Non-tobacco Consumers: never-smokers/never-ST users whose ECO was 0 to 5 ppm (a range of 6 to 10 ppm was allowed upon joint review by the Sponsor and Investigator).

- Male, between 26 and 49 years of age, inclusive (on Day 1 check-in).

- Free of clinically significant health problems in the opinion of the Investigator.

- Forced expiratory volume exhaled in one second (FEV1) =70% of predicted at Screening.

- Willing to undergo all study procedures during confinement.

- Not taking medication on a daily basis for chronic medical disorders deemed clinically significant by the Investigator.

- Willing to suspend usage of daily aspirin or over-the-counter (OTC) medication seven days prior to Day 1.

- Not taking any creatine supplements.

- Negative tests for selected drugs of abuse and alcohol at Screening and at Day 1 check-in.

- Able to read and comprehend questionnaires in English.

- Able to comprehend and willing to sign an Informed Consent Form (ICF).

Exclusion Criteria:

- At Screening, a BP that exceeds 140/90.

- <70% predicted FEV1 from three acceptable maneuvers.

- Unwilling to have the FMD procedure performed two or more times during confinement.

- Unwilling to have the ABI procedure performed two times during confinement.

- For the FMD determination, poor brachial artery visualization due to extremely deep position or severe artifacts (noise) due to overlying muscle that, in the sonographer(s)' opinion, would result in an inferior, unreadable or unobtainable brachial artery image.

- A donation of blood from 30 days prior to Screening through Day 1, inclusive, or of plasma from two weeks prior to Screening through Day 1, inclusive.

- Receipt of blood products within two months prior to Day 1 check-in.

- Evidence of visible oral cancer, as found in an oral health examination at Screening or based on oral health questions at Day 1 check-in.

- Subject who is an employee of the clinical site.

- Subject who has participated in any other investigational study drug or product trial in which receipt of an investigational study drug or product occurred within 30 days prior to Day 1 check-in, inclusive.

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Intervention

Other:
Subject's usual brand (UB) tobacco product
For SMK: UB of cigarettes; For MSC: UB of moist snuff

Locations

Country Name City State
United States MDS Pharma Services (US), Inc. (Currently Celerion) Lincoln Nebraska

Sponsors (6)

Lead Sponsor Collaborator
R.J. Reynolds Tobacco Company Analytisch-biologisches Forschungslabor GmbH, BioClinica, Inc., MDS Pharma Services, Pacific Biomarkers, Rules-Based Medicine, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (8)

Campbell LR, Brown BG, Jones BA, Marano KM, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure. Inhal Toxicol. 2015 Feb;27(3):149-56. doi: 10.3109/08958378.2015.1013228. Epub 2015 Mar 19. — View Citation

Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. — View Citation

Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006 Aug;8(4):600-22. Review. — View Citation

Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol. 2010 Jun 21;23(6):1001-8. doi: 10.1021/tx100056m. — View Citation

Marano KM, Kathman SJ, Jones BA, Nordskog BK, Brown BG, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol. 2015 — View Citation

Nordskog BK, Brown BG, Marano KM, Campell LR, Jones BA, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol. 2015 Feb;27(3):157-66. doi: 10.3109/08958378.2015.1013227. E — View Citation

Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, Pechacek TF, Howard G; American Heart Association Council on Cardiovascular Nursing. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010 Oct 12;122(15):1520-44. doi: 10.1161/CIR.0b013e3181f432c3. Epub 2010 Sep 13. — View Citation

Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Reduct J. 2006 Dec 21;3:37. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Buccal cells Determination of the feasibility and utility of using buccal cells to distinguish DNA methylation and gene expression differences (conducted as a post-hoc evaluation) Day 2 (fasting) No
Primary Ankle-Brachial Index (ABI-C) Non-invasive "functional" technique based on differential leg-arm blood pressure; aids in diagnosis of peripheral artery disease.
Comparison of ABI-C among the three cohorts.
Afternoon of Day 1, ~15 minutes after completion of a "tobacco product challenge" No
Primary Flow-mediated Dilation (FMD-C) Non-invasive "functional" imaging technique to evaluate vascular tone of the brachial artery; indicator of individual's overall cardiovascular health.
Comparison of FMD-C among the three cohorts.
Afternoon of Day 1, ~30 minutes after completion of a "tobacco product challenge" and following ABI-C No
Primary Ankle-Brachial Index (ABI-F) Non-invasive "functional" technique based on differential leg-arm blood pressure; aids in diagnosis of peripheral artery disease.
Comparison of ABI-F among the three cohorts.
Morning of Day 2 (fasting) measured immediately after vitals were obtained No
Primary Flow-mediated Dilation (FMD-F) Non-invasive "functional" imaging technique to evaluate vascular tone of the brachial artery; indicator of individual's overall cardiovascular health.
Comparison of FMD-F among the three cohorts.
Morning of Day 2 (fasting) measured immediately after ABI was obtained No
Primary Carotid Intima-media Thickness (CIMT-F) Non-invasive "morphological" imaging technique used to measure the thickness of the intima-media region of the carotid artery to detect presence/absence of atherosclerotic plaques.
Comparison of CIMT-F among the three cohorts.
Morning of Day 2 (fasting) immediately after FMD was obtained No
Primary Urine Biomarkers of Tobacco Effect (EffBio[U]-C) Comparison of select CVD-related blood biomarkers among the three cohorts. Afternoon of Day 1, ~15 minutes after completion of a "tobacco product challenge" No
Primary Urine Biomarkers of Tobacco Effect (EffBio[U]-F) Comparison of select CVD-related urine biomarkers among the three cohorts. Morning of Day 2 (fasting) from the first morning void collection No
Primary Blood Biomarkers of Tobacco Effect (EffBio[B]-F) Comparison of select CVD-related urine biomarkers among the three cohorts. Morning of Day 2 (fasting) after first morning void was obtained No
Primary Urine Biomarkers of Tobacco Exposure (ExpBio[U]-C) Comparison of tobacco-specific and tobacco-related blood biomarkers among the three cohorts. Afternoon of Day 1, ~15 minutes after completion of a "tobacco product challenge" No
Primary Blood Biomarkers of Tobacco Exposure (ExpBio[B]-C) Comparison of tobacco-specific and tobacco-related blood biomarkers among the three cohorts. Afternoon of Day 1, ~15 minutes after completion of a "tobacco product challenge" and following the urine collection No
Primary Urine Biomarkers of Tobacco Exposure (ExpBio[U]-F) Comparison of tobacco-specific and tobacco-related blood biomarkers among the three cohorts. Morning of Day 2 (fasting) from the first morning void collection No
Primary Blood Biomarkers of Tobacco Exposure (ExpBio[B]-F) Comparison of tobacco-specific and tobacco-related blood biomarkers among the three cohorts. Morning of Day 2 (fasting) after first morning void was obtained No
Secondary Health status scores from self-administered questionnaires on health, nicotine dependence and diet Comparison of the self-reported health status measures between the three cohorts All questionnaires: Administered once on evening of Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment